Crizanlizumab is an effective medication for preventing vaso-occlusive crises in sickle cell anemia patients.
Crizanlizumab Market: Introduction
Crizanlizumab is an effective medication for preventing vaso-occlusive crises in sickle cell anemia patients. It is a therapy for people 16 and older who suffer from vaso-occlusive crises, a severe consequence of sickle cell disease that occurs when blood circulation is blocked by sickled red blood cells.
Read Report Overview - https://www.transparencymarketresearch.com/crizanlizumab-market.html
Sickle cell disease is characterized by the presence of sickle hemoglobin, chronic hemolysis, recurrent pain episodes, multiorgan dysfunction, and early death. Sickle cell–related pain crises are the primary cause of health care encounters in patients with sickle cell disease. These crises result in a decrease in quality of life and an increase in the risk of death. Crises are thought to be caused by vascular occlusion in the microcirculation, increased inflammation, and alterations in nociception.
The prevention of crises could minimize or prevent tissue and organ damage and decrease the subsequent risk of death among patients with sickle cell disease. Crizanlizumab, an antibody against the adhesion protein P-selectin, was tested in sickle cell disease patients for safety and effectiveness. Crizanlizumab treatment was linked with a reduced risk of sickle cell–related pain crises than placebo, as well as a low number of side events.
Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=82889
Key Drivers, Restrains, and Opportunities of Global Crizanlizumab Market
Increase in prevalence of sickle cell anemia drives the crizanlizumab market. Approximately 5% of the world’s population carries trait genes for hemoglobin disorders, primarily sickle-cell disease and thalassaemia. Hemoglobin disorders are genetic blood diseases due to the inheritance of mutant hemoglobin genes from both, generally healthy, parents. Over 300 000 babies with severe hemoglobin disorders are born each year.
Sickle cell disease (SCD) affects millions of people throughout the world and is particularly common among those whose ancestors came from sub-Saharan Africa; Spanish-speaking regions in the Western Hemisphere such as South America, the Caribbean, and Central America, Saudi Arabia, India, and Mediterranean countries such as Turkey, Greece, and Italy.
It is estimated that sickle cell disease affects approximately 100,000 people in the U.S, and occurs among about 1 out of every 365 Black or African-American births; sickle cell disease occurs among about 1 out of every 16,300 Hispanic-American births, about 1 in 13 Black or African-American babies is born with sickle cell trait (SCT).
Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=82889
However, stringent regulatory requirements and high cost are major factors that are likely to hamper the market
Governments in developing countries are making significant investments to modernize healthcare infrastructure, which is likely to increase access to healthcare. This is expected to increase the demand for crizanlizumab. Increase in prevalence of sickle cell in developing countries presents lucrative opportunities for the crizanlizumab market.
North America to Capture Major Share of Global Crizanlizumab Market
North America is expected to account for a major share of the global crizanlizumab market due to high prevalence of sickle cell anemia among the population. Moreover, well- established healthcare infrastructure and hub for key industry players are major drivers of the crizanlizumab market in the region.
The crizanlizumab market in Asia Pacific is estimated to expand at a rapid pace during the forecast period owing to a rise in healthcare infrastructure. Moreover, a surge in population coupled with sickle cell disease is likely propel the market in the region.
Pre Book Crizanlizumab Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=82889<ype=S
Key Players Operating in Global Crizanlizumab Market
The FDA approved crizanlizumab, a monoclonal antibody developed by Novartis, on November 15, 2019. Crizanlizumab aims to reduce the frequency of painful vaso-occlusive crisis, which are painful and can lead to life-threatening conditions. Moreover, they are a major cause of additional costs such as hospitalization.
Browse More Trending Reports by Transparency Market Research:
Urinary Catheters Market: Continuous advances in urinary catheterization, both in relation to materials used and the techniques themselves, have built up sizable demand in urinary catheters market. Various types of catheters are used, mainly including intermittent catheters, foley catheters, and male external catheters, for emptying the bladder.
Chromoendoscopy Agents Market: This report analyzes the current scenario and future prospects of the global chromoendoscopy agents market. Rise in prevalence of gastrointestinal diseases, technological advancements in imaging techniques, surge in awareness among people about preventive measures of cancer, and increase in the number of endoscopy procedures are factors projected to propel the global market during the forecast period.
Advanced Wound Care Management Market: The highly fragmented nature of the wound dressings market has encouraged market players to shift focus toward relatively niche segments such as advanced wound dressings. Venous ulcer, diabetic foot ulcers, and pressure ulcers are major types of chronic wounds, while surgical and burn cases are major type of acute wounds.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.
Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.
TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
Contact
Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/